<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819024</url>
  </required_header>
  <id_info>
    <org_study_id>2015-174</org_study_id>
    <secondary_id>NCI-2016-00881</secondary_id>
    <secondary_id>2015-174</secondary_id>
    <secondary_id>P30CA022453</secondary_id>
    <nct_id>NCT02819024</nct_id>
  </id_info>
  <brief_title>Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography</brief_title>
  <official_title>Study of the Effects of Dexamethasone on Non-Small Cell Lung Cancer Using [F-18] FLT for Imaging With Positron Emission Tomography (PET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot research trial studies the effects of dexamethasone in patients with non-small
      cell lung cancer that has not responded after previous treatment. Drugs such as dexamethasone
      can affect how tumors grow and respond to treatments. Imaging tests, such as
      fluoro-L-thymidine (FLT) positron emission tomography , use a small amount of radioactive
      substance to show changes in tumor cells. Studying the effects of dexamethasone on lung
      tumors using FLT positron emission tomography may help doctors plan better treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the effect of dexamethasone (Dex) treatment in patients with relapsed
      non-small cell lung cancer (NSCLC) using 3'-fluorothymidine (FLT) positron emission
      tomography (PET) as measured by changes in tumor maximum standardized uptake value (SUVmax).

      SECONDARY OBJECTIVES:

      I. Assess the reversibility of Dex-mediated changes in tumor FLT retention following the
      withdrawal of Dex.

      II. Measure tumor Glucocorticoid Receptor alpha expression (GRα) from recent patient biopsy
      samples.

      III. Analyze blood samples obtained during imaging to determine serum Dex concentration and
      for senescence markers in circulating tumor cells.

      OUTLINE:

      Patients receive dexamethasone orally (PO) twice daily (BID) on days 1-5. Patients undergo 3
      fluorothymidine F-18 (18F)-FLT PET scans. One scan within 7 days prior to the start of
      dexamethasone, one scan on day 3 after the 5th dose of dexamethasone, and one scan 6-9 days
      after the last dose of dexamethasone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in tumor SUVmax assessed by 18F-FLT PET imaging</measure>
    <time_frame>Baseline to day 9</time_frame>
    <description>The primary analysis is one sample t-test for the change of SUVmax.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in senescence markers in circulating tumor cells</measure>
    <time_frame>Baseline to day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum dexamethasone concentration</measure>
    <time_frame>Baseline to day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dexamethasone withdrawal as measured by changes in tumor FLT retention</measure>
    <time_frame>Day 6-9</time_frame>
    <description>Secondary analyses will be carried out with descriptive statistics such as mean, SD, range. Correlation analysis will be descriptive. Spearman correlation coefficient will be calculated and scatter plot will be plotted. Subgroup analyses for dexamethasone withdrawal will be performed within the GRα high group. All subgroup analyses will be descriptive due to the expected small sample size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor glucocorticoid receptor alpha expression</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Recurrent Non-Small Cell Lung Carcinoma</condition>
  <condition>Stage IIIA Non-Small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-Small Cell Lung Cancer</condition>
  <condition>Stage IV Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (dexamethasone, 18F-FLT PET)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive dexamethasone PO BID on days 1-5. Patients undergo 3 18F-FLT PET scans. One scan within 7 days prior to the start of dexamethasone, one scan on day 3 after the 5th dose of dexamethasone, and one scan 6-9 days after the last dose of dexamethasone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given PO BID</description>
    <arm_group_label>Treatment (dexamethasone, 18F-FLT PET)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>Visumetazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Device for PET</intervention_name>
    <description>Undergo 18F-FLT PET scan</description>
    <arm_group_label>Treatment (dexamethasone, 18F-FLT PET)</arm_group_label>
    <other_name>18F-FLT</other_name>
    <other_name>3'-Deoxy-3'-(18F) Fluorothymidine</other_name>
    <other_name>3'-deoxy-3'-[18F]fluorothymidine</other_name>
    <other_name>Fluorothymidine F 18</other_name>
    <other_name>FLUOROTHYMIDINE F-18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (dexamethasone, 18F-FLT PET)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo 18F-FLT PET scan</description>
    <arm_group_label>Treatment (dexamethasone, 18F-FLT PET)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET SCAN</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically proven advanced non-squamous NSCLC.
             Patients may have newly diagnosed recurrent progressive or refractory disease which
             may be localized or wide spread.

          -  No chemotherapy for at least 4 weeks and no radiation to the index lesion or clear
             progression in that lesion (greater than 20% increase in longest diameter).

          -  Life expectancy of greater than 4 weeks

          -  Absolute neutrophil count &gt;= 1,000/mcL (measured within 2 weeks of registration)

          -  No history of human immunodeficiency virus (HIV) or active infections

          -  No history of diabetes

          -  No surgery in the last 2 weeks prior to study enrollment

          -  Has not received Dex or another corticosteroid in over 4 weeks prior to enrollment

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Agreed to FLT-PET imaging and signed consent and eligible FLT-PET protocol 2006-127

          -  Registered with the clinical trials office of the Karmanos Cancer Center/Wayne State
             University

        Exclusion Criteria:

          -  Patients must have measureable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded) as &gt;=
             20 mm with conventional techniques (computed tomography [CT], magnetic resonance [MR]
             or PET); lesions in the previously irradiated area can be considered as measureable
             lesions as long as there has been an increase of at least 10 mm when compared to
             measurements obtained after completion of radiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Shields</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony F. Shields</last_name>
      <phone>313-576-8735</phone>
      <email>shieldsa@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Anthony F. Shields, Ph.D, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anteneh Tesfaye, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manish Thakur, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoinette Wozniak, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ammar Sukari, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Larry Matherly, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manohar Ratnam, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulka N. Vaishampayan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amy Weise, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Misako Nagasaka, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elon Knoll, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammad Chisti, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seraphim Pallas, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Anthony Shields</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Dideoxynucleosides</mesh_term>
    <mesh_term>Alovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

